| Bioactivity | Poloxipan is a pan-specific polo-like kinase (PLK) inhibitor that can inhibit a non-catalytic region at the C-terminus called the Polo-box domain (PBD) found in kinases. The IC50 values for Poloxipan against the PBDs of PLK-1/2/3 are 3.2 μM, 1.7 μM, and 3.0 μM, respectively. Poloxipan also inhibits other phospho-tyrosine binding domains, such as the forkhead-associated (FHA) domain of CHK-2, the WW domain of peptidyl-prolyl cis/trans isomerase (PIN1), and the phospho-tyrosine binding domains of STAT1/3/5 and lymphocyte-specific protein tyrosine kinase's SH2 domain. Poloxipan can be used in cancer research[1]. |
| CAS | 1239513-63-3 |
| Formula | C14H10BrN3O3S |
| Molar Mass | 380.22 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kumar S, et al. PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis. Biomed Res Int. 2015;2015:705745. |
Poloxipan
CAS: 1239513-63-3 F: C14H10BrN3O3S W: 380.22
Poloxipan is a pan-specific polo-like kinase (PLK) inhibitor that can inhibit a non-catalytic region at the C-terminus c
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.